PRS vs REGN · rev $70.41B vs P/E 14, rev $14.34B
Prudential Financial, Inc. 5.62 (PRS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Prudential Financial, Inc. 5.62 (PRS) common stock listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PRS revenue for 2024-12-31 was $70.41B. Net income was $2.85B. Revenue was up 366.8% from 2023-12-31 to 2024-12-31. PRS currently screens at market cap $44.13B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PRS currently screens at market cap $44.13B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PRS and REGN stock pages for the full models.
Not investment advice.